Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914168 | 0.86 | PTGER1 (0.64) | PTGER1MRGPRX4SLC6A4 | |
| SCHEMBL4775728 | 0.83 | ALDH1A1 (0.48) | MEN1KMT2ASLC6A4NPC1MAPK1 | |
| SCHEMBL14034917 | 0.83 | NPC1 (0.44) | MEN1KMT2AATMNPC1MAPK1 | |
| SCHEMBL4774815 | 0.78 | POLB (0.44) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9789583 | 0.77 | PTGER1 (0.61) | PTGER1MRGPRX4KMT2A | |
| SCHEMBL21434703 | 0.77 | PTGER1 (0.57) | PTGER1MRGPRX4KMT2ANPC1RAB9A | |
| SCHEMBL6630996 | 0.73 | PTGER1 (0.56) | PTGER1MRGPRX4SLC6A4 | |
| SCHEMBL7911112 | 0.71 | MAOB (0.57) | PTGER1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7910948 | 0.71 | MAOB (0.57) | PTGER1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3915952 | 0.71 | PPIA (0.47) | PTGER1MRGPRX4KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885MRGPRX4 96/4885MEN1 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.